Loukia Apostolakopoulou

Dr. Loukia Apostolakopoulou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
MCMatteo Castaldo
Matteo Castaldo
MWMarta Waliszewska-Prosół
Marta Waliszewska-Prosół
MKMaria Koutsokera
Maria Koutsokera
MRMicaela Robotti
Micaela Robotti
MSMarcin Straburzyński
Marcin Straburzyński
O(On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
Background: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods: We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results: Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions: Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.

1 May 2019 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
VZVasiliki Zouvelou
Vasiliki Zouvelou
DYDelia Yubero
Delia Yubero
LALoukia Apostolakopoulou
Loukia Apostolakopoulou
EKEleftheria Kokkinou
Eleftheria Kokkinou
MBManolis Bilanakis
Manolis Bilanakis
RPRoser Pons
Roser Pons

29 September 2023 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AAArife Çimen Atalar
Arife Çimen Atalar
AAAyşe Nur Özdağ Acarlı
Ayşe Nur Özdağ Acarlı
BBBetül Baykan
Betül Baykan
PMPaolo Martelletti
Paolo Martelletti
HBHayrunnisa Bolay
Hayrunnisa Bolay
AÖAynur Özge
Aynur Özge
Background: Although acute headache following COVID-19 vaccination is widely acknowledged, the long-term progression of these headaches remains poorly understood. Our objective was to identify various phenotypes of prolonged or worsened headaches associated with COVID-19 vaccination and document any changes in these phenotypes over an extended period. Additionally, we aimed to document the diverse headache presentations among patients with pre-existing primary headaches. Methods: A multinational, prospective observational study was conducted to investigate prolonged or worsened headaches associated with COVID-19 vaccination. Questionnaires assessing COVID-19 vaccination-related headaches at three time points (initial visit, 3rd month follow-up, and 6th month follow-up) were developed for the study. Headache specialists/clinicians evaluated patients using these questionnaires in a prospective manner. Repeated K-means cluster analysis was performed to identify patient profiles with prolonged or worsened headaches related to COVID-19 vaccination. Results: Among the 174 patients included in the study, there was a female-to-male ratio of 128 (73.6%) to 46 (26.4%). The mean age of the patient group was 45.2 ± 13.3 years, and 107 patients (61.5%) had a pre-existing history of primary headaches. Through the analysis, two major clusters were identified based on headache characteristics at each visit. During the first visit (n = 174), Cluster 1 primarily comprised patients with a history of primary headaches, frontal localization of pain, throbbing pain type, more severe headaches accompanied by symptoms such as nausea, phonophobia, photophobia, and osmophobia, and worsened by physical activity. In contrast, Cluster 2 consisted of patients with longer headache durations (over one month) and a stabbing/pressing quality of pain. Patients in Cluster 1 had a higher prevalence of migraine as the pre-existing primary headache disorder compared to Cluster 2 (90.48% vs. 68.18%, respectively; p = 0.005). Conclusion: The identification of two distinct phenotypes of prolonged or worsened headaches related to COVID-19 vaccination can provide valuable clinical insights. Having an awareness of the potential worsening of headaches following COVID-19 vaccination, particularly in patients with a primary headache disorder such as migraine, can help clinicians and headache experts anticipate and adjust their treatment strategies accordingly. This knowledge can aid in preplanning treatment modifications and optimize patient care.

13 April 2023 in Epilepsy & Behavior
Verified
Journal Article
Open access
LALoukia Apostolakopoulou
Loukia Apostolakopoulou
PVPilar Bosque Varela
Pilar Bosque Varela
FRFabio Rossini
Fabio Rossini
COCiara O'SUllivan
Ciara O'SUllivan
WLWolfgang Löscher
Wolfgang Löscher
ETEugen Trinka
Eugen Trinka
Topiramate (TPM) is widely used in focal and generalized epilepsies. It is commercially available as tablets and sprinkles capsules for oral treatment. Previous studies comparing intravenous (IV) to oral TPM in healthy adults showed more rapid pharmacodynamic effects in cases of IV administration. Despite promising findings, no clinical application in humans followed. We present a case of a pregnant woman with idiopathic generalized epilepsy who experienced a generalized tonic-clonic seizure in the third trimenon due to low TPM levels attributed to pregnancy followed by repeated prolonged absences. We applied a new meglumine-based solution (1%) of TPM (10 mg/ml) in two IV infusions of 200 mg each under EEG monitoring over a total duration of 1 hour. The infusion was well tolerated and led to a rapid increase in plasma TPM levels. A clinical as well as electroencephalographic improvement was documented within the first hours. To the best available knowledge, this is the first reported case where IV TPM was used therapeutically for seizure treatment in humans. It is also the first time that the new meglumine-based solution was used in a human with epilepsy. The advantages of IV route delivery and the solution's quick preparation, high tolerability, and low toxicity make it ideal for use in many clinical settings and high-care patients. IV TPM seems to be a reasonable adjunctive option for adults with seizures, previously stabilized on oral TPM, who need rapid plasma concentration boosting. Although our experience was successful in using injectable TPM in seizure emergencies, randomized controlled clinical trials are required to make recommendations for the use of IV TPM on patients with epilepsy. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022 in Salzburg, Austria.

18 November 2021 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
LALoukia Apostolakopoulou
Loukia Apostolakopoulou

28 September 2025 in Brain Research
Verified
Journal Article
Open access
IVIoannis Vlachos
Ioannis Vlachos
CMCHRISTOS MOSCHOVOS
CHRISTOS MOSCHOVOS
LALoukia Apostolakopoulou
Loukia Apostolakopoulou
KKKyriaki Karasavvidou
Kyriaki Karasavvidou
EDEva Danassi
Eva Danassi
AKAndreas Kyrozis
Andreas Kyrozis
Relatively little is known about EEG high γ (gamma) range changes in Alzheimer's disease (AD). We investigated functional connectivity, focusing on the γ range, in amnestic Mild Cognitive Impairment (MCI) using ordinary Coherence (COH) and Partial Coherence (PCOH), a metric which enhances signal to noise ratio at high frequencies. MCI (N=21) and Cognitively normal (CN, N=62) ALBION study participants had resting EEG with eyes closed (EC) and eyes open (EO) in 10/20 montage (19 active electrodes). COH and PCOH in 0.5-100 Hz for each subject were calculated for all 171 electrode pairs. In both γ1 (30-50 Hz) and γ2 (50-100 Hz) ranges, PCOH was significantly higher in MCI than in CN in several electrode pairs, especially centrally, in both eye conditions. Concerning local (average of each electrode) connectivity, MCI compared to CN showed significantly higher values in PCOH centrally. Resting EEG γ range functional connectivity at central areas, as revealed by PCOH, is significantly higher in MCI than in CN. γ range local and regional EEG functional connectivity differences may help construct useful and easily available biomarkers in neurodegeneration. Metrics, such as PCOH, which factor out global connectivity components may help reveal such differences.